术前经皮微泡造影增强超声用于乳腺癌前哨淋巴结识别与活检:四中心经验对比
比较英国四家中心使用皮内微泡造影增强超声(CEUS)术前识别并活检乳腺癌前哨淋巴结(SLN)的经验。四中心SLN成功活检率为77.5%–88%,识别全部SLN转移的敏感度为45.5%–52.5%,特异度为96.3%–100%,阴性预测值为84.5%–87.0%。作者认为该技术可重复,在腋窝保腋窝治疗时代有潜力替代手术分期。
要点
- 皮内微泡CEUS可术前定位并核心活检SLN,四中心成功率为77.5%–88%,操作可重复。
- 识别全部SLN转移的敏感度为45.5%–52.5%,特异度为96.3%–100%,阴性预测值为84.5%–87.0%。
- 中心1和2中,微泡CEUS SLN活检良性者术后分别有1.6%(12/730)和4%(7/181)发现≥2枚淋巴结宏转移。
核心结论
- 使用CEUS识别并活检SLN是一项可重复的技术。
- 在腋窝保腋窝治疗时代,微泡CEUS SLN核心活检有潜力替代腋窝手术分期。
研究设计与样本
- 研究比较英国四家中心使用皮内微泡和CEUS术前识别并活检乳腺癌SLN的经验,数据收集于2010年至2016年。
- 中心1为前瞻性序贯纳入1361例,中心2为回顾性序贯纳入376例,中心3为回顾性选择纳入121例,中心4为前瞻性选择纳入48例。
- 所有中心患者均在腋窝手术前接受微泡CEUS SLN核心活检,中心1和中心2患者腋窝灰阶超声正常。
诊断标准与关键数值
- SLN成功核心活检率:中心1为80%,中心2为79.6%,中心3为77.5%,中心4为88%。
- 识别全部SLN转移的敏感度:中心1为46.9%[95%CI(39.4-55.1)],中心2为52.5%[95%CI(39.1-65.7)],中心3为46.4%[95%CI(27.5-66.1)],中心4为45.5%[95%CI(16.7-76.6)]。
- 特异度:中心1为99.7%[95%CI(98.9-100)],中心2为98.1%[95%CI(94.5-99.6)],中心3为100%[95%CI(93.2-100%)],中心4为96.3%[95%CI(81-99.9)]。
- 阴性预测值:中心1为87.0%[95%CI(84.3-89.3)],中心2为84.5%[95%CI(78.4-89.5)],中心3为86.9%[95%CI(82.4-90.3)],中心4为86.2%[95%CI(78.4-91.5)]。
- 中心1和中心2中,微泡CEUS SLN核心活检为良性的患者,在初次手术治疗结束时发现≥2枚淋巴结宏转移的比例分别为12/730(1.6%)和7/181(4%)。
临床应用与阅片要点
- 术前可采用皮内微泡CEUS识别并核心活检SLN,四中心操作成功率为77.5%–88%,技术可重复。
- 微泡CEUS SLN核心活检良性者仍分别在中心1有1.6%(12/730)、中心2有4%(7/181)于术后发现≥2枚淋巴结宏转移。
- 作者认为在腋窝保腋窝治疗时代,微泡CEUS SLN核心活检有潜力替代腋窝手术分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the experience of four UK Centres in the use of intradermal microbubbles and contrast enhanced ultrasound (CEUS) to pre-operatively identify and biopsy sentinel lymph nodes (SLN) in patients with breast cancer.
METHODS: In all centres, breast cancer patients had a microbubble/CEUS SLN core biopsy prior to axillary surgery and patients in Centres 1 and 2 had a normal greyscale axillary ultrasound. Data were collected between 2010 and 2016; 1361 from Centre 1 (prospective, sequential), 376 from Centre 2 (retrospective, sequential), 121 from Centre 3 (retrospective, selected) and 48 from Centre 4 (prospective, selected).
RESULTS: SLN were successfully core biopsied in 80% (Centre 1), 79.6% (Centre 2), 77.5% (Centre 3) and 88% (Centre 4). The sensitivities to identify all SLN metastases were 46.9% [95% confidence intervals (CI) (39.4-55.1)], 52.5% [95% CI (39.1-65.7)], 46.4% [95% CI (27.5-66.1)] and 45.5% [95% CI (16.7-76.6)], respectively. The specificities were 99.7% [95% CI (I98.9-100)], 98.1% [95% CI (94.5-99.6)], 100% [95% CI (93.2-100%)] and 96.3% [95% CI (81-99.9)], respectively.The negative predictive values were 87.0% [95% CI (84.3-89.3)], 84.5% [95% CI (78.4-89.5)], 86.9% [95% CI (82.4-90.3)] and 86.2% [95% CI (78.4-91.5)], respectively. At Centres 1 and 2, 12/730 (1.6%) and 7/181 (4%), respectively, of patients with a benign microbubble/CEUS SLN core biopsy had two or more lymph node (LN) macrometastases found at the end of primary surgical treatment.
CONCLUSION: The identification and biopsy of SLN using CEUS is a reproducible technique. Advances in knowledge: In the era of axillary conservation, microbubble/CEUS SLN core biopsy has the potential to succeed surgical staging of the axilla.
引用
- Cox K, Taylor-Phillips S, Sharma N, et al. Enhanced pre-operative axillary staging using intradermal microbubbles and contrast-enhanced ultrasound to detect and biopsy sentinel lymph nodes in breast cancer: a potential replacement for axillary surgery. Br J Radiol. 2017. PMID: 29125333. doi:10.1259/bjr.20170626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。